Kelly Kimbrell, APRN
Family · Oklahoma City, OKNPI 1881105161
Payments from drug & device makers
Across 163 payments — averaging $19.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mayne Pharma Commercial LLC$479
- AbbVie$440
- Pfizer$232
- Sage Therapeutics, LLC$204
- Sumitomo Pharma America, Inc.$170
- Bayer$159
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,14799%
- Education$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mayne Pharma Commercial LLC | 18 | $479 |
| AbbVie | 24 | $440 |
| Pfizer | 14 | $232 |
| Sage Therapeutics, LLC | 12 | $204 |
| Sumitomo Pharma America, Inc. | 8 | $170 |
| Bayer | 10 | $159 |
| Minerva Surgical, Inc | 4 | $147 |
| Millicent US Inc | 8 | $139 |
| Daiichi Sankyo Inc. | 6 | $138 |
| Avion Pharmaceuticals | 6 | $118 |
| Hologic Sales And Service, LLC | 5 | $105 |
| Exeltis, USA Inc. | 5 | $102 |
| Organon | 5 | $74 |
| Astellas Pharma US Inc | 4 | $65 |
| Myovant Sciences Inc. | 3 | $61 |
| Agile Therapeutics, Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Shield Therapeutics Inc | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $36 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $34 |
| Scynexis, Inc. | 2 | $32 |
| Vertex | 2 | $32 |
| Therapeuticsmd, Inc. | 2 | $28 |
| AstraZeneca | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $21 |
| Medtronic | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Ascend Therapeutics US, LLC | 1 | $16 |
| Pacira Pharmaceuticals Incorporated | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Merck | 1 | $14 |
| Evofem Biosciences, Inc. | 1 | $14 |
How this compares
$3,166 in reported general payments places this provider in the 85th percentile of 2,026 family providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 30 | $1,293 |
| ProgesteroneProgesterone, Micronized | 28 | $1,221 |
| Estradiol (Twice Weekly)Estradiol | 18 | $1,124 |
| Spironolactone | 17 | $244 |
Paid to pharmacies, not to this prescriber.
Other family in Oklahoma City
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Lacey HillOklahoma City$20K
- Julia John SamuelOklahoma City$17K
- Kristina SnyderOklahoma City$15K
- Lindi CiglarOklahoma City$15K
- Shymol JohnOklahoma City$14K
- Xiomara PorrasOklahoma City$12K
- Anne DudeOklahoma City$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.